GlobeNewswire Clinical StudiesOriginal article
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Data ReadoutpositivelorundrostatPositive
AI Analysis
Summary
Mineralys Therapeutics presented positive data from the pivotal Launch-HTN trial showing lorundrostat 50 mg achieved the AHA/ACC systolic blood pressure target of <130 mmHg in 46% of difficult-to-treat hypertension patients at 12 weeks, with over two-thirds achieving ≥10 mmHg reduction.
Clinical Trial Data
Phase
Phase_3
Primary Endpoint
Met
Outcome Details
46% of participants achieved systolic blood pressure target of <130 mmHg at 12 weeks; more than two-thirds achieved ≥10 mmHg systolic blood pressure reduction
Importance:6/10
Sentiment:
0.70
hypertensioncardiovascularclinical_datalorundrostatdifficult-to-treat hypertension
Read the original article
Published by GlobeNewswire Clinical Studies on October 9, 2026 1:00 PM